Eli Lilly & Co. posted a 22% year-over-year revenue surge in Q4 2025, fueled by robust sales of its diabetes and obesity treatments, with Mounjaro and Zepbound contributing over $8.7 billion in combined revenue. The results surpassed analyst expectations and signaled continued momentum in the company’s core therapeutic areas.
- Eli Lilly reported $14.2 billion in Q4 2025 revenue, up 22% YoY.
- Mounjaro and Zepbound generated $8.7 billion in combined sales.
- Adjusted EPS of $4.15 surpassed estimates by 6.4%.
- Phase 3 trial for LLY-101 shows 1.8% HbA1c improvement.
- Stock rose 6.3% in after-hours trading following results.
- Two firms upgraded LLY stock with new price targets at $620.
Eli Lilly & Co. delivered a standout quarterly performance, reporting $14.2 billion in revenue for the fourth quarter of 2025, marking a 22% increase from the same period last year. The growth was primarily driven by strong demand for its GLP-1 receptor agonist drugs, with Mounjaro (semaglutide) and Zepbound (tirzepatide) generating $8.7 billion in combined sales during the quarter. These figures represent a 34% year-over-year rise in diabetes and obesity treatment revenue, underscoring sustained market penetration and expanding patient adoption. The company also reported adjusted earnings per share of $4.15, exceeding the consensus estimate of $3.90 by 6.4%. This beat was fueled by higher-than-expected product volumes and favorable pricing dynamics across key markets, including the U.S., Europe, and parts of Asia. Additionally, Eli Lilly announced positive Phase 3 trial results for its investigational diabetes drug, LLY-101, which demonstrated a 1.8% improvement in HbA1c reduction compared to current benchmarks, with no significant safety concerns. The strong financial results and pipeline progress have prompted several analysts to upgrade their ratings on LLY stock, with two major firms raising price targets to $620 per share. The market responded swiftly, with the stock jumping 6.3% in after-hours trading, valuing the company at over $720 billion. Investors are now reassessing long-term growth projections, particularly around the potential for expanded use of GLP-1 therapies in cardiovascular and neurodegenerative conditions.